NEW HAVEN, Conn., Nov. 13, 2014 /PRNewswire/ -- MediciGlobal has launched a new website on behalf of Trevi Therapeutics, Inc.® ("Trevi" or the "Company") to provide access to information on a clinical trial for prurigo nodularis, considered one of the most severe forms of pruritus (chronic itching).
Prurigo nodularis, also known as nodular prurigo, is characterized by painful nodules (bumps) that itch so intensely that the perpetual cycle of itch, scratch, bleed, and scarring lasts for years or even decades. As a result, prurigo nodularis can negatively affect a person's quality of life—interfering with daily activities, social interactions, and sleep. Since there are currently no approved treatments for prurigo nodularis, patients are keen to support the advancement of new treatment options.
Prurigo nodularis is receiving increasing attention in the medical community, and is helped in part by the clinical trial currently sponsored by Trevi. The study website—www.ChronicItch.com—explains that Trevi's clinical research study is designed to see how well and safely the study drug works at reducing severe, chronic itching in people with prurigo nodularis, and that the results of this study may help to provide a better anti-itch treatment option for prurigo nodularis sufferers. The website also allows patients to pre-screen online to see whether they meet the medical requirements to enroll in the study, what they can expect, and where the study is being conducted.
The intensity of constant itching of prurigo nodularis is so unbearable that a survey recently conducted by MediciGlobal, in preparation for Trevi's clinical trial and its website, found that more than a third of all prurigo nodularis patients were willing to travel anywhere (regardless of distance) to seek out treatment, and 95% of respondents want to find a clear diagnosis and an effective treatment including clinical trials participation.
The clinical trial is limited to 60 qualified participants, so prurigo nodularis patients and their doctors are being encouraged to visit the study website (www.ChronicItch.com) before the opportunity to enroll in the study closes.
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a development-stage biotechnology company focused on developing Nalbuphine ER for chronic pruritus (itch). Pruritus develops in various dermatologic, metabolic, hematologic, and neuropathic conditions. The Company is pursuing two conditions for clinical development: uremic pruritus and prurigo nodularis. Uremic pruritus is a persistent and debilitating itch in patients on dialysis that has been associated with increased mortality. Prurigo nodularis is a chronic dermatologic condition characterized by severely pruritic nodules on the skin that are independent of underlying etiology. There are no approved therapies in the United States or European Union for either condition.
Nalbuphine ER is an oral extended release opioid with a unique opioid receptor dual agonist/antagonist mechanism of action, which has shown efficacy in addressing pruritus in both animal studies and human clinical trials. Because of Nalbuphine ER's dual mechanism of action, the company believes it can have broad utility in treating chronic pruritus.
Founded in 2011, Trevi is headquartered in New Haven, CT, USA.
For additional information, visit www.TreviTherapeutics.com .
Headquartered in the United States and Europe, MediciGlobal is an industry leader in the precision use of social media and internet-based technologies to connect patients with clinical trials to advance new medicines. Its more than 30 Facebook communities, including Chronic Itch - Prurigo Nodularis (www.Facebook.com/ChronicItch), collectively exceed 1 million fans and more than 12 million visitors weekly. MediciGlobal believes in helping patients gain access to new medical treatments through clinical trials and reduce clinical research costs by enrolling clinical trials faster.
The Company's clinical trial recruitment practices are guided by global standards and a concern for the lives of those who put their trust in the company to be matched to the right clinical trial. The MediciGlobal team also ensures that those participate in these trials fully understand the clinical trial process, and that their participation is guarded by strict privacy policies. MediciGlobal meets BBB OnLine® and WBENC (Women's Business Enterprise National Council) accreditation standards; it is also certified as a Safe Harbor company.
Founded in 1991, MediciGlobal is headquartered in King of Prussia, PA, USA.
For additional information, visit www.MediciGlobal.com.